OBIO Orchestra BioMed Holdings, Inc.
$5.55▼ -0.72%
Healthcare
Other
Volume 242.7K
Avg Volume (10D) 375.5K
Key Metrics & Fundamentals
Market Cap
$333.58M
P/E Ratio
–
Div Yield
0.00%
52W Range
3.46 - 6.50
% vs 50 MA
-1.86%
% vs 200 MA
23.16%
RSI-14
46.2
MACD Histogram
-0.0500
Beta (1Y vs SPY)
1.44
Free Cash Flow
-$19.59M
Gross Rev
$88,000
Gross Profit
$63,000
EBITDA
-$22.63M
COGS
$25,000
Operating Exp
$22.42M
Operating Income
-$22.36M
EBIT
-$22.36M
Pretax Income
-$23.76M
Net Income
-$23.76M
EPS (Diluted)
-0.38
Price & Volume History
Loading chart…
Recent News
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
GlobeNewswire · Oct 22, 2026 8:30 AM ET
OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports
Investing.com · Oct 20, 2026 2:35 PM ET
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
GlobeNewswire · Oct 1, 2026 8:00 AM ET
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Zacks · Sep 21, 2026 7:33 AM ET
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
GlobeNewswire · Sep 16, 2026 8:30 AM ET
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
GlobeNewswire · Sep 15, 2026 8:30 AM ET
B. Riley Adjusts Orchestra BioMed Price Target to $11 From $10, Maintains Buy Rating
MT Newswires · Sep 15, 2026 7:34 AM ET
Orchestra BioMed Shares Rise After BTIG Upgrade
MT Newswires · Sep 10, 2026 3:11 PM ET
BTIG Upgrades Orchestra BioMed to Buy From Neutral, Price Target is $10
MT Newswires · Sep 10, 2026 6:59 AM ET
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 2, 2026 4:05 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See OBIO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.